Influenza Virus Susceptibility and Resistance to Oseltamivir

  title={Influenza Virus Susceptibility and Resistance to Oseltamivir},
  author={Fred Y. Aoki and Guy Boivin and Noel Allan Roberts},
  journal={Antiviral Therapy},
  pages={603 - 616}
Oseltamivir phosphate is a prodrug of oseltamivir carboxylate, a highly specific inhibitor of influenza virus neuraminidases. Given that oseltamivir carboxylate binds to highly conserved, essential amino acids in the catalytic site of the enzyme, and that the activity of neuraminidase is critical for virus release from infected cells and subsequent virus spread, the drug was expected to have a low propensity to select for viable resistant mutants. Indeed, viruses with neuraminidase (and… 

Figures and Tables from this paper

Evolution of the Influenza A Virus Genome during Development of Oseltamivir Resistance In Vitro

It is concluded that only selection of H 274Y is required for oseltamivir resistance and that H274Y is not deleterious in the absence of the drug, and these collective results could offer an explanation for the recent reproducible rise in oselTamavir resistance in seasonal H1N1 IAV strains in humans.

Resistance Development to Influenza Virus Sialidase Inhibitors

The emergence of influenza viruses resistant to sialidase (neuraminidase, NA) inhibitors (NAIs) upon treatment is observed at low frequencies in adult immunocompetent patients, and does not impact significantly the evolution of influenza syndrome but H1N1 viruses naturally resistant to oseltamivir did emerge and spread in 2007–2008, which compromises the clinical effectiveness of the drug.

Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets

In conclusion, viral fitness of the H274Y pH1N1 isolate is not substantially altered and has the potential to induce severe disease and to disseminate.

Detection of Resistance Mutations to Antivirals Oseltamivir and Zanamivir in Avian Influenza A Viruses Isolated from Wild Birds

Resistant strains were more frequently found in Ottenby samples than in NCBI data sets, and it is still uncertain if these mutations are the result of natural variations in the viruses or if they are induced by the selective pressure of xenobiotics.

Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal

Evidence of circulation of drug-resistant seasonal A(H1N1) viruses during the 2008 influenza season (July to September) in Senegal is provided and the results are in favor of multiple introductions of oseltamivir resistant viruses (ORV), suggesting sequential introductions in Africa.

Antiviral Resistance in Influenza Viruses: Clinical and Epidemiological Aspects

  • F. Hayden
  • Medicine, Biology
    Antimicrobial Drug Resistance
  • 2009
Infl uenza epidemiology in temperate climates is expected to provide some protection against widespread circulation of resistant variants, as viruses do not persist between epidemics but rather are re-introduced each season and new variants appear often.

Systematic review of influenza resistance to the neuraminidase inhibitors

It is demonstrated that that a substantial number of patients may become oseltamivir-resistant as a result of osel Tamsiflu-resistant use, and that oselTAMivir resistance may be significantly associated with pneumonia.

I223R Mutation in Influenza A(H1N1)pdm09 Neuraminidase Confers Reduced Susceptibility to Oseltamivir and Zanamivir and Enhanced Resistance with H275Y

Concomitant emergence of the I223R and H275Y mutations under oseltamivir treatment underlines the importance of close monitoring of treated patients especially those immunocompromised.



Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors

It is indicated that different patterns of susceptibility and cross-resistance between NA inhibitors may prove important if antiviral resistance to zanamivir and oseltamivIR were to emerge.

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir

The baseline susceptibilities prior to and shortly after the introduction of the NA inhibitors are established and there was no evidence of naturally occurring resistance to either drug in any of the isolates.

Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.

In this population, influenza B viruses with reduced sensitivity to neuraminidase inhibitors do not arise as frequently as resistant influenza A viruses, however, they appear to be transmitted within communities and families, requiring continued close monitoring.

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.

The data indicate that the current methods for monitoring resistant mutants are potentially flawed because no tissue culture system adequately reflects the receptor specificity of human respiratory tract epithelium.

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

Hemagglutinin affinity for receptors is an essential feature of influenza virus susceptibility to NA inhibitors, both in cell culture and in humans.

Treatment of influenza with neuraminidase inhibitors: virological implications.

  • N. Roberts
  • Biology, Medicine
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences
  • 2001
Evaluation of the emergence of influenza virus resistance to neuraminidase inhibitors (NAIs) is now demanded following experience with amantadinamines. Preliminary data have indicated that


Oseltamivir administered daily for six weeks by the oral route is safe and effective for the prevention of influenza.